Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma

Pathogenesis beyond the cancer clone(s) in multiple myeloma

(2015) G. Bianchi et al.   BLOOD

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment

(2015) A. Ponzetta et al.   CANCER RESEARCH

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity

(2015) G.V. Duarte et al.   CYTOKINE

CXCR3 ligands in disease and therapy

(2015) Katrien Van Raemdonck et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The effects of age and gender on plasma levels of 63 cytokines

(2015) Anders Larsson et al.   JOURNAL OF IMMUNOLOGICAL METHODS

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

(2015) B Paiva et al.   LEUKEMIA

Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice

(2015) Mara Kornete et al.   PLoS One

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies

(2015) T Dosani et al.   Blood Cancer Journal

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

(2014) M. A. Mir et al.   BLOOD

Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells

(2014) Thibaud André et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human monocytes have increased IFN-γ-mediated IL-15 production with age alongside altered IFN-γ receptor signaling

(2014) Naeun Lee et al.   CLINICAL IMMUNOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Heparanase enhances myeloma progression via CXCL10 downregulation

(2014) U Barash et al.   LEUKEMIA

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

(2013) Daniel Heintel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma

(2013) Kai-Ping Chang et al.   ORAL ONCOLOGY

Serum CXCL9 Levels Are Associated with Tumor Progression and Treatment Outcome in Patients with Nasopharyngeal Carcinoma

(2013) Li-Jen Hsin et al.   PLoS One

Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD

(2012) J. E. Croudace et al.   BLOOD

Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

(2012) Sergio Rutella et al.   Clinical & Developmental Immunology

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma

(2012) Walter M. T. Braga et al.   Clinical & Developmental Immunology

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

(2012) R. J. Pessoa de Magalhaes et al.   HAEMATOLOGICA

CXCR3 Chemokine Receptor-Ligand Interactions in the Lymph Node Optimize CD4+ T Helper 1 Cell Differentiation

(2012) Joanna R. Groom et al.   IMMUNITY

Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent

(2012) Sylvia Feyler et al.   PLoS One

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

(2011) M. Hong et al.   CANCER RESEARCH

CXCR3 in T cell function

(2011) Joanna R. Groom et al.   EXPERIMENTAL CELL RESEARCH

Increase of Circulating CXCL9 and CXCL11 Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis

(2011) Alessandro Antonelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment

(2011) J. R. Nair et al.   JOURNAL OF IMMUNOLOGY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer

(2011) Ole Audun Werner Haabeth et al.   Nature Communications

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients

(2010) Yanran Cao et al.   EXPERIMENTAL HEMATOLOGY

Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression

(2010) Dagmar Berghuis et al.   JOURNAL OF PATHOLOGY

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage

(2009) T. Yamashita et al.   CLINICAL CANCER RESEARCH

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

(2008) H. Ludwig et al.   BLOOD